Google Ad

FDC launches 2 variants of Favipiravir in India at Rs 55 per pill – Home Health Choices

Drug agency FDC Ltd on Tuesday stated it has launched two variants of the COVID-19 drug Favipiravir underneath the model names PiFLU and Favenza. The Drug Controller General of India (DCGI) had earlier permitted using Favipiravir, an off patent, oral antiviral drug that has been proven to quicken scientific restoration in COVID-19 sufferers with gentle to reasonable signs, FDC stated in an announcement.

“Early diagnosis and treatment will help in arresting the deteriorating condition of patients, and we will be working with the government and healthcare fraternity to make Favenza and PiFLU available across the country” FDC spokesperson Mayank Tikkha stated.

Both the merchandise are at present accessible throughout the nation, the corporate stated.

The value per pill is Rs 55 for each the variants, it added.

Shares of FDC Ltd closed at Rs 317.50 per scrip on BSE, down 1.17 per cent over earlier shut.

Follow and join with us on , Facebook, Linkedin

Latest Updates

Related Post